NO20041983L - C-5-modifiserte indazolylprrolotriaziner - Google Patents

C-5-modifiserte indazolylprrolotriaziner

Info

Publication number
NO20041983L
NO20041983L NO20041983A NO20041983A NO20041983L NO 20041983 L NO20041983 L NO 20041983L NO 20041983 A NO20041983 A NO 20041983A NO 20041983 A NO20041983 A NO 20041983A NO 20041983 L NO20041983 L NO 20041983L
Authority
NO
Norway
Prior art keywords
indazolylprrolotriazines
modified
modified indazolylprrolotriazines
Prior art date
Application number
NO20041983A
Other languages
English (en)
Other versions
NO20041983D0 (no
Inventor
Gregory D Vite
James G Tarrant
Harold Mastalerz
Guifen Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20041983D0 publication Critical patent/NO20041983D0/no
Publication of NO20041983L publication Critical patent/NO20041983L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/009After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone characterised by the material treated
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/45Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements
    • C04B41/4584Coating or impregnating of particulate or fibrous ceramic material
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B2111/00Mortars, concrete or artificial stone or mixtures to prepare them, characterised by specific function, property or use
    • C04B2111/00474Uses not provided for elsewhere in C04B2111/00
    • C04B2111/00793Uses not provided for elsewhere in C04B2111/00 as filters or diaphragms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Photoreceptors In Electrophotography (AREA)
NO20041983A 2001-11-14 2004-05-13 C-5-modifiserte indazolylprrolotriaziner NO20041983L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33301401P 2001-11-14 2001-11-14
PCT/US2002/036528 WO2003042172A2 (en) 2001-11-14 2002-11-12 C-5 modified indazolylpyrrolotriazines

Publications (2)

Publication Number Publication Date
NO20041983D0 NO20041983D0 (no) 2004-05-13
NO20041983L true NO20041983L (no) 2004-06-24

Family

ID=23300880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041983A NO20041983L (no) 2001-11-14 2004-05-13 C-5-modifiserte indazolylprrolotriaziner

Country Status (24)

Country Link
US (2) US6908916B2 (no)
EP (1) EP1446401B1 (no)
JP (1) JP4301440B2 (no)
KR (1) KR20050044441A (no)
CN (1) CN1615306A (no)
AR (1) AR037368A1 (no)
AT (1) ATE524462T1 (no)
BR (1) BR0214112A (no)
CA (1) CA2467068A1 (no)
ES (1) ES2370709T3 (no)
HR (1) HRP20040422A2 (no)
HU (1) HUP0402566A3 (no)
IL (1) IL161616A0 (no)
IS (1) IS7243A (no)
MX (1) MXPA04004492A (no)
NO (1) NO20041983L (no)
NZ (1) NZ533034A (no)
PE (1) PE20030712A1 (no)
PL (1) PL368909A1 (no)
RU (1) RU2004117549A (no)
TW (1) TW200300350A (no)
UY (1) UY27540A1 (no)
WO (1) WO2003042172A2 (no)
ZA (1) ZA200403694B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
WO2003091229A1 (en) 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
BR0309669A (pt) 2002-04-23 2005-03-01 Bristol Myers Squibb Co Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
US7388009B2 (en) 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
PT1506203E (pt) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
BRPI0407282A (pt) 2003-02-05 2006-01-31 Bristol Myers Squibb Co Processo para preparação de inibidores de pirrolotriazina cinase
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
ES2319462T3 (es) 2005-03-28 2009-05-07 Bristol-Myers Squibb Company Inhibidores competitivos de atp cinasas.
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
DE102006030479A1 (de) * 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
KR20120065321A (ko) * 2009-07-28 2012-06-20 우베 고산 가부시키가이샤 피롤로〔2,3-d〕피리미딘 유도체
CN102627647A (zh) * 2012-03-20 2012-08-08 南京药石药物研发有限公司 4-氯-5-甲基-1H-吡咯并[2,1-f][1,2,4]三嗪的合成方法
EP2948454B1 (en) 2013-01-24 2017-05-31 Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) Triazine compounds and a process for preparation thereof
JP6473146B2 (ja) 2013-10-11 2019-02-20 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ピロロトリアジンキナーゼ阻害剤
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908056A (en) 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
ES2200039T3 (es) 1995-12-08 2004-03-01 Pfizer Inc. Derivados heterociclicos sustituidos como antagonistas de crf.
ES2273369T3 (es) 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
ES2258459T3 (es) * 1999-05-21 2006-09-01 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas.
WO2001014378A1 (en) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
WO2003091229A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases

Also Published As

Publication number Publication date
WO2003042172A3 (en) 2004-01-29
HUP0402566A3 (en) 2009-01-28
EP1446401B1 (en) 2011-09-14
JP2005509030A (ja) 2005-04-07
HUP0402566A2 (hu) 2005-03-29
WO2003042172A2 (en) 2003-05-22
BR0214112A (pt) 2004-09-14
IS7243A (is) 2004-04-30
MXPA04004492A (es) 2004-08-11
US6908916B2 (en) 2005-06-21
NO20041983D0 (no) 2004-05-13
ATE524462T1 (de) 2011-09-15
CN1615306A (zh) 2005-05-11
US20050209235A1 (en) 2005-09-22
KR20050044441A (ko) 2005-05-12
NZ533034A (en) 2004-11-26
AR037368A1 (es) 2004-11-03
IL161616A0 (en) 2004-09-27
ES2370709T3 (es) 2011-12-22
RU2004117549A (ru) 2006-01-10
UY27540A1 (es) 2003-07-31
EP1446401A2 (en) 2004-08-18
EP1446401A4 (en) 2006-04-12
HRP20040422A2 (en) 2005-04-30
JP4301440B2 (ja) 2009-07-22
PE20030712A1 (es) 2003-08-21
TW200300350A (en) 2003-06-01
CA2467068A1 (en) 2003-05-22
US20030186983A1 (en) 2003-10-02
ZA200403694B (en) 2006-06-28
PL368909A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
IS7243A (is) C-5 breytt indazólýlpýrrólótríazín
DK1671949T3 (da) Substituerede pyridinylaminer
DE50204184D1 (de) Espressobrüheinrichtung
DE50103741D1 (de) Welle-Nabe-Verbindung
DE50208022D1 (de) Wischblatt
DE50204386D1 (de) Kreuztransducer
DE50206021D1 (de) Schlauchklemme
DE50209238D1 (de) Kugelgelenk
DE50206892D1 (de) Substituierte imidazotriazinone
DE50204551D1 (de) Kugelgelenk
DE50208372D1 (de) Schrankaufhängevorrichtung
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE50203412D1 (de) Schwenkkolbenverdränger
DE50203984D1 (de) Kugelgelenk
ATE355059T1 (de) Isoxazolopyridinone
DE50208029D1 (de) Kugelgelenk
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
DE50201862D1 (de) Messwandler
DE50203093D1 (de) Losradlager
ATA18372001A (de) Gelenksbolzenbaueinheit
ATE319694T1 (de) Phenylalkyne
DE50209293D1 (de) Amidpolymermasse
DE50207815D1 (de) Kugelgelenk
DE50202088D1 (de) Garmodulsystem
ATA13992002A (de) Schlackengranulierungsanlage

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application